Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Dan Schell
03.18.25 -- Business of Biotech Newsletter
By the end of this month, we'll have worked our way through the special series of Business of Biotech episodes recorded and filmed on-site at the JP Morgan Healthcare conference, where we were graciously hosted by some wonderful lawyers (those words don't have to be mutually exclusive) at the law offices of Alston & Bird. Big thanks to those folks, and to Life Science Leader's Ben Comer for joining me on several of these.
08.20.24 -- Business Of Biotech Newsletter
In the business of ProFound Therapeutics, Umoja Biopharma, Immunity Bio, Poseida Therapeutics, and more! We're closing in fast on 600,000 downloads of the Business of Biotech podcast, and while that "vanity metric" is fun to watch, it's not what I get most excited about. What gets me excited and puts fuel to the Business of Biotech engine is the interaction with listeners, the feedback, the constructive criticism, the guest suggestions, the picks and the pans.
06.18.24 -- ABCs Of ADCs
In the Business of Daiici Sankyo, Vincerx, Mythic Therapeutics, and more! Back-to-back episodes of the Business of Biotech found us talking ADCs with two biotech builders on opposite ends of the continuum last month. On episode 203, Mythic Therapeutics CSO Brian Fiske, Ph.D. painted the picture of his company’s early efforts, focusing on Mythic’s buildout as it develops an ADC pipeline. The following week, Daiichi Sankyo, Inc.
05.21.24 -- Business Of Biotech Newsletter
Newsletter | May 21, 2024 In the business of the FDA, Immunity Bio, Orna Therapeutics, Tome Biosciences, and more! The past few weeks have produced some of our best work, and that’s a direct reflection of the incredible guests we’ve hosted. I’m not just talking about their credentials and experience, either. I’m talking about their incredible displays of humanity.
Do ClinOps Professionals Understand The CAR-T Supply Chain
By Dan Schell, Chief Editor, Clinical Leader You know what you don't hear a lot about when planning for a clinical trial? Weather. But when you're talking about a CAR-T therapy, weather events such as hurricanes, tornadoes, floods, and snowstorms become part of the conversation. After all, these are personalized medicines that need to be manufactured and delivered back to the patient usually in tight time frames.
Make phishing great again. VSTO office files are the new macro nightmare?
Visual Studio Tools for Office (VSTO) has the capability to export an Add-In which is embedded inside an Office document file (such as a Word DOCX). If this document is delivered in the right way (to avoid some inbuilt mitigations) it provides rich capabilities for attackers to phish users and gain code execution on a remote machine through the installation of a word Add-In. Office itself even provides an automatic update capability, which can be used by attackers to update payloads remotely.
ON CAMPUS: A second career | The Belleville Intelligencer
Leslie Nixon spent years working in retail before landing her first dream job at a daycare in Barry’s Bay, Ontario. After six months, the daycare closed its doors and she found herself without a job. At the age of 39, she had no idea what to do next. Living in a small, rural community, where job opportunities are limited, she found herself looking for a new career. Nixon considered her interests and explored her passions. Caring for people was at the top of her list.
Lean, Not Mean: How To Increase Your Competitiveness And Maximize Profitability
5 free* articles every 30 days, from Life Science Leader Access to industry leading content and analysis on issues shaping the pharmaceutical landscape Digital newsletters throughout the month covering topics that you want to read about Access on the device of your choice: smartphone, tablet, or desktop Topic specific content covering key areas such as Outsourcing, Clinical Research and Pharmaceutical Manufacturing
The Changing Business Of Drug Development
5 free* articles every 30 days, from Life Science Leader Access to industry leading content and analysis on issues shaping the pharmaceutical landscape Digital newsletters throughout the month covering topics that you want to read about Access on the device of your choice: smartphone, tablet, or desktop Topic specific content covering key areas such as Outsourcing, Clinical Research and Pharmaceutical Manufacturing
A View From The Top: Q&A With AstraZeneca CEO David Brennan
5 free* articles every 30 days, from Life Science Leader Access to industry leading content and analysis on issues shaping the pharmaceutical landscape Digital newsletters throughout the month covering topics that you want to read about Access on the device of your choice: smartphone, tablet, or desktop Topic specific content covering key areas such as Outsourcing, Clinical Research and Pharmaceutical Manufacturing
The Transformation Of Sanofi-Aventis U.S.
5 free* articles every 30 days, from Life Science Leader Access to industry leading content and analysis on issues shaping the pharmaceutical landscape Digital newsletters throughout the month covering topics that you want to read about Access on the device of your choice: smartphone, tablet, or desktop Topic specific content covering key areas such as Outsourcing, Clinical Research and Pharmaceutical Manufacturing
Biosimilars Event Chairperson Not What I Expected
As the editorial director of Life Science Leader (LSL), I’m not the guy you see at conferences and trade shows; that’s the job of our Chief Editor, Rob Wright. Instead, I’m the one working behind the scenes coordinating with Rob and our other editors and writers on what articles will run and when. So it was unusual that I ventured out from our HQ in Erie, PA to attend the Biosimilars World Congress in San Diego recently. Am I an expert in biosimilars?
A Last Look at the Congress Theater Before its Rebirth
If you’re a Logan Square resident saddened by the lack of screaming, brawling crowds in front of the Congress Theater, the time to rejoice is now. The Congress is making a comeback. Saturday, 1st Ward Alderman Proco Joe Moreno hosted a open house tour of the historic venue, closed since April 2013 and in desperate need of repair, to show off plans for just that very thing: an extensive renovation.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Dan
Contact Dan, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack